141206-42-0
141206-42-0
Chemical Structure
Lucerastat
Synonym(s): NB-DGJ; N-(n-Butyl)deoxygalactonojirimycin
- CAS No.: 141206-42-0
- Formula:C10H21NO4
- Molecular Weight:219.28
IUPAC Name: (2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
InChIKey: UQRORFVVSGFNRO-XFWSIPNHSA-N
SMILES: O[C@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O
Biological Activity: Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lucerastat | 98.0% | Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lucerastat (Standard) | ≥98% | Lucerastat (Standard) is the analytical standard of Lucerastat. This product is intended for research and analytical applications. Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
